Apr 12–15, 2026 | Fairmont Hotel Vancouver, Vancouver, BC, Canada
Scientific Organizers:
Matthias Kretzler, Hiddo Lambers Heerspink, Olga G. Troyanskaya, and Maria Chiara Magnone

-
Scientific Organizers: Matthias Kretzler, Hiddo Lambers Heerspink, Olga G. Troyanskaya, and Maria Chiara Magnone
Matthias Kretzler, MD
University of Michigan
Hiddo Lambers Heerspink, PhD
University Medical Center Groningen
Olga G. Troyanskaya, PhD
Princeton University
Maria Chiara Magnone, PhD
Janssen Inc.
***Meeting program subject to change.
Available Formats: = Livestream = In Person = On DemandSunday, April 12, 2026
Fundraising
Booking Function
Merchandise Options
Registration Options
Monday, April 13, 2026
Building the Village of Precision Medicine for Kidney Disease: NIDDK Vision for CKD in 2026
Modelling Kidney Function: What Renal Physiology Teaches us in 2025 for CKD: Lessons Learned from Modeling Endothelin Function in CKD Trials
Kidney Tissue Bioengineering for Patient Level Precision Medicine
Ex vivo Organ Cross Talk: Liver-Kidney System Defines Molecular Cross Talk in Toxin Induced CKD
Tissue is the Issue: AI Driven Image Analysis Maps Structural and Molecular Disease Trajectories
From Mapping to Mechanism to Medicine
Genes and Environment Driving CKD: Linking Environmental Exposures with Genetic Risk Assessment to Guide CKD Management
Tuesday, April 14, 2026
Obesity Driven Metabolic Reprogramming: From Metabolic Profiling to Drug Targets for Cardiorenal Disease
Finally Breaking the Death Spiral of CKD: Mechanistic Trials Defining the Mode of Action of the Incretin System
Innate Immunity Modulation in Lupus Nephritis, Bringing Insight from Trials Back to the Bench
The Right Drug for the Right IgAN in 2025: Impact of Endothelin Blockade on Glomerular Manifestations of IgA Nephritis
Understanding Filtration Barrier Failure Drives Novel Treatments in Nephrotic Syndrome
Wednesday, April 15, 2026
Polycystic Kidney Disease: The Journey from Gene to Therapies
ApoL1 Biology and Kidney Disease
ApoL1 across Continents: Lessons Learned on Gene Environment Interaction in H3 Africa KDRN
Lessons Learned from the First Trials Targeting ApoL1 Kidney Disease
Lessons Learned from Matching Patients Renal Pathobiology to Targeted Therapies in Glomerular Disease
Platform Trials in CKD, State of the Art in 2026
Precision Medicine Trials in CKD: Bringing Molecular Understanding of CKD Drugs to Clinical Care
Thursday, April 16, 2026
Subscribe for Updates